The DEA's Final Rescheduling Decision Is Expected Late 2026 — Three Scenarios
CRC Manufacturing · September 5, 2026 · 3 min read
The broader rescheduling proceeding is in its final procedural stretch, and there is no statutory deadline forcing it to conclude. For a manufacturer, the outcome is mostly a tax question — but the preparation is identical under all three plausible endings.
Where the process stands
The expedited hearing ran from June 29 to July 15, 2026. The administrative law judge is now reviewing post-hearing briefs and is expected to issue a recommendation in late 2026. Participants then have 20 days to file objections.
After that, the DEA Administrator issues the final decision. There is no statutory deadline on that step, so it could land in late 2026 or slip into early 2027. Separately, a challenge to the April 23 order is pending in the D.C. Circuit, which could complicate or reopen what has already been issued.
Scenario A: full Schedule III
The Administrator extends Schedule III treatment to all state-licensed marijuana, adult-use included. Section 280E stops applying to licensed operators, which converts a large category of currently non-deductible expenses back into ordinary deductions.
Second-order effects follow over quarters rather than weeks: banking and payment processing become easier to underwrite, cost of capital falls at the margin, and clinical research becomes materially more feasible. This is the outcome the industry is modeling, but it is not the only one on the table.
Scenario B: medical-only holds
The April 23 order stands as issued: FDA-approved products and state-licensed medical products sit in Schedule III, while adult-use marijuana remains Schedule I. The IRS has signaled that 280E relief is likely limited to medical operations unless broader rescheduling happens.
For a California manufacturer whose volume is adult-use, this is functionally the status quo on taxes. It also creates an accounting incentive to distinguish medical from adult-use activity cleanly, because the deductibility of a shared cost may depend on which side of that line it falls.
Scenario C: litigation delays everything
Objections, the D.C. Circuit challenge, or a change in agency posture push the final decision well past early 2027. Nothing changes on the ground, and any plan that assumed 280E relief in the 2026 or 2027 tax year has to be unwound.
This is the scenario most worth budgeting for, because it is the one that requires no new action from anyone. Administrative processes without deadlines tend to take the time available to them.
What to do regardless of outcome
Every scenario rewards the same three things, and none of them require guessing. They also happen to be what a lender, an acquirer, or an auditor asks for.
- Keep clean books with expenses categorized well enough to restate under either tax treatment
- Separate medical and adult-use cost accounting now, so Scenario B does not require reconstructing a year of records
- Lock in supply and production agreements at known per-unit rates while pricing is soft
- Model 2027 with 280E still applying; treat relief as upside rather than plan
Timing note
All of the above is forward-looking. The ALJ recommendation is expected, not scheduled, and the Administrator's decision has no deadline. Verify current status before making a tax election or a financing decision that depends on it.